IN2014DN10088A - - Google Patents
Info
- Publication number
- IN2014DN10088A IN2014DN10088A IN10088DEN2014A IN2014DN10088A IN 2014DN10088 A IN2014DN10088 A IN 2014DN10088A IN 10088DEN2014 A IN10088DEN2014 A IN 10088DEN2014A IN 2014DN10088 A IN2014DN10088 A IN 2014DN10088A
- Authority
- IN
- India
- Prior art keywords
- dementia
- salt
- disease
- senile dementia
- senile
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
A camsylate salt of (1r, 1 'R, 4R)- 4- methoxy- 5' -methyl- 6'- [5- (prop -1- yn 1 -yl)pyridin- 3- yl]- 3' H- dispiro[cyclohexane- 1, 2'- inden- r2' imidazole]- 4' -amine , pharmaceutical compositions containing the salt and therapeutic uses of the salt for treating Aß related pathologies such as Alzheimer' s Disease , Down' s syndrome, ß- amyloid angiopathy and conditions such as dementia including dementia of mixed vascular and degenerative origin , pre- senile dementia , senile dementia and dementia associated with Parkinson s disease, progressive supranuclear palsy or cortical basal degeneration.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662592P | 2012-06-21 | 2012-06-21 | |
| PCT/GB2013/051606 WO2013190302A1 (en) | 2012-06-21 | 2013-06-20 | Camsylate salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN10088A true IN2014DN10088A (en) | 2015-08-21 |
Family
ID=48746084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN10088DEN2014 IN2014DN10088A (en) | 2012-06-21 | 2013-06-20 |
Country Status (42)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8415483B2 (en) | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
| US9650336B2 (en) | 2011-10-10 | 2017-05-16 | Astrazeneca Ab | Mono-fluoro beta-secretase inhibitors |
| US9000183B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors |
| US9000184B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors |
| US9000185B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cycloalkyl ether compounds and their use as BACE inhibitors |
| US9000182B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | 2H-imidazol-4-amine compounds and their use as BACE inhibitors |
| UY36347A (en) | 2014-10-07 | 2016-04-01 | Astrazeneca Ab | COMPOUNDS AND ITS USE AS BACE INHIBITORS |
| JP6546410B2 (en) * | 2015-02-23 | 2019-07-17 | ローム株式会社 | Power supply apparatus, AC adapter, AC charger, electronic device and power supply system |
| TW201740944A (en) | 2016-03-15 | 2017-12-01 | 美國禮來大藥廠 | Combination therapy |
| JP2019511500A (en) * | 2016-03-15 | 2019-04-25 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | Combination of BACE inhibitors and antibodies or antigen binding fragments for the treatment of disorders associated with accumulation of amyloid beta |
| JP2022525157A (en) * | 2019-03-14 | 2022-05-11 | アストラゼネカ・アクチエボラーグ | Lana Becestat for Weight Loss |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100452491B1 (en) * | 2001-03-29 | 2004-10-12 | 한미약품 주식회사 | A novel crystalline amlodipine camsylate and a preparing method thereof |
| JP4273406B2 (en) | 2001-06-01 | 2009-06-03 | 小野薬品工業株式会社 | A therapeutic agent for demyelinating disease or demyelinating disease containing aldose reductase inhibitor as an active ingredient |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| DE602005017129D1 (en) | 2004-03-22 | 2009-11-26 | Lilly Co Eli | Pyridyl derivatives and their use as MGLU5 receptor antagonists |
| AR054617A1 (en) | 2005-06-14 | 2007-07-04 | Schering Corp | PIRROL DERIVATIVES [3, 4 - D] PYRIMIDINE AS INHIBITORS OF ASPARTIL PROTEASES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM |
| TW200734311A (en) * | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
| JP2009520686A (en) | 2005-11-21 | 2009-05-28 | アストラゼネカ・アクチエボラーグ | Novel 2-amino-imidazol-4-one compounds and their use in the manufacture of a medicament for use in the treatment of cognitive impairment, Alzheimer's disease, neurodegeneration and dementia |
| CA2633992A1 (en) | 2005-12-21 | 2007-07-05 | Boehringer Ingelheim International Gmbh | Pyrimidine derivatives useful as inhibitors of pkc-theta |
| WO2007100536A1 (en) | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
| WO2007146225A2 (en) | 2006-06-12 | 2007-12-21 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| WO2008076044A1 (en) | 2006-12-20 | 2008-06-26 | Astrazeneca Ab | Novel 2-amino-5, 5-diaryl-imidazol-4-ones |
| EP2108018A2 (en) | 2007-02-01 | 2009-10-14 | Glaxo Group Limited | 8-oxa-1,4-diazaspiro [4,5] dec-3-en-1-yl and 1,4,8-triazaspiro [4,5] dec-3-en-1-yl acetamides as glyti transporter inhibitors in treatment of neurological and neuropsychiatric disorders |
| AU2008248129B8 (en) | 2007-05-07 | 2013-05-30 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| WO2009100169A1 (en) | 2008-02-06 | 2009-08-13 | Glaxo Group Limited | Dual pharmacophores - pde4-muscarinic antagonistics |
| FR2929943B1 (en) * | 2008-04-15 | 2010-09-24 | Inst Rech Developpement Ird | 2-SUBSTITUTED QUINOLINE SALTS |
| EP2318416B1 (en) | 2008-07-28 | 2013-09-04 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
| US8450308B2 (en) | 2008-08-19 | 2013-05-28 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
| US8426447B2 (en) | 2008-09-11 | 2013-04-23 | Amgen Inc. | Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use |
| PT2406240E (en) | 2009-03-13 | 2016-02-24 | Boehringer Ingelheim Int | Inhibitors of beta-secretase |
| TW201103893A (en) | 2009-07-02 | 2011-02-01 | Astrazeneca Ab | New compounds |
| AR077447A1 (en) | 2009-07-02 | 2011-08-31 | Astrazeneca Ab | BETA-SECRETASE INHIBITING COMPOUNDS, USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
| EP2539322B1 (en) | 2010-02-24 | 2014-01-01 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
| AR080865A1 (en) | 2010-03-31 | 2012-05-16 | Array Biopharma Inc | DERIVATIVES OF SPIROTETRAHYDRONAFTALENE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESS OF PREPARATION AND USE OF THEM TO TREAT NEURODEGENERATIVE DISEASES, AS ALZHEIMER. |
| WO2011130741A1 (en) | 2010-04-16 | 2011-10-20 | Array Biopharma Inc. | Compounds for treating neurodegenerative diseases |
| EP2601197B1 (en) | 2010-08-05 | 2014-06-25 | Amgen Inc. | Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use |
| WO2012040641A2 (en) | 2010-09-24 | 2012-03-29 | Array Biopharma Inc. | Compounds for treating neurodegenerative diseases |
| AR083953A1 (en) | 2010-11-22 | 2013-04-10 | Array Biopharma Inc | COMPOUNDS TO TREAT NEURODEGENERATIVE DISEASES |
| US8415483B2 (en) | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
| US9650336B2 (en) | 2011-10-10 | 2017-05-16 | Astrazeneca Ab | Mono-fluoro beta-secretase inhibitors |
| US9000184B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors |
| US9000182B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | 2H-imidazol-4-amine compounds and their use as BACE inhibitors |
| US9000185B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cycloalkyl ether compounds and their use as BACE inhibitors |
| US9000183B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors |
-
2013
- 2013-06-13 US US13/916,754 patent/US10548882B2/en active Active
- 2013-06-19 AR ARP130102162 patent/AR091495A1/en unknown
- 2013-06-20 JP JP2015517850A patent/JP2015520221A/en active Pending
- 2013-06-20 WO PCT/GB2013/051606 patent/WO2013190302A1/en active Application Filing
- 2013-06-20 KR KR1020147035069A patent/KR102123708B1/en active IP Right Grant
- 2013-06-20 AP AP2014008137A patent/AP2014008137A0/en unknown
- 2013-06-20 AU AU2013279109A patent/AU2013279109B2/en active Active
- 2013-06-20 RU RU2014148305A patent/RU2638175C2/en active
- 2013-06-20 EP EP16162104.0A patent/EP3064494A1/en not_active Withdrawn
- 2013-06-20 PE PE2014002451A patent/PE20150670A1/en active IP Right Grant
- 2013-06-20 BR BR122016014302-3A patent/BR122016014302B1/en active IP Right Grant
- 2013-06-20 NZ NZ702742A patent/NZ702742A/en not_active IP Right Cessation
- 2013-06-20 DK DK13733415.7T patent/DK2864316T3/en active
- 2013-06-20 PT PT137334157T patent/PT2864316T/en unknown
- 2013-06-20 CA CA2875589A patent/CA2875589C/en active Active
- 2013-06-20 ES ES13733415.7T patent/ES2618939T3/en active Active
- 2013-06-20 AP AP2017009693A patent/AP2017009693A0/en unknown
- 2013-06-20 SG SG11201407934UA patent/SG11201407934UA/en unknown
- 2013-06-20 UA UAA201412619 patent/UA114196C2/en unknown
- 2013-06-20 MX MX2014014709A patent/MX354214B/en active IP Right Grant
- 2013-06-20 SI SI201330561A patent/SI2864316T1/en unknown
- 2013-06-20 HU HUE13733415A patent/HUE033376T2/en unknown
- 2013-06-20 CN CN201380033030.6A patent/CN104411697B/en active Active
- 2013-06-20 MA MA39259A patent/MA39259B1/en unknown
- 2013-06-20 LT LTEP13733415.7T patent/LT2864316T/en unknown
- 2013-06-20 BR BR112014031531-0A patent/BR112014031531B1/en active IP Right Grant
- 2013-06-20 NZ NZ727045A patent/NZ727045A/en not_active IP Right Cessation
- 2013-06-20 RS RS20170236A patent/RS55815B1/en unknown
- 2013-06-20 IN IN10088DEN2014 patent/IN2014DN10088A/en unknown
- 2013-06-20 PL PL13733415T patent/PL2864316T3/en unknown
- 2013-06-20 EP EP13733415.7A patent/EP2864316B1/en active Active
- 2013-06-20 CN CN201610570484.2A patent/CN106279102A/en active Pending
- 2013-06-21 TW TW102122259A patent/TWI588140B/en not_active IP Right Cessation
- 2013-06-21 TW TW106115007A patent/TWI639591B/en not_active IP Right Cessation
-
2014
- 2014-11-25 TN TN2014000491A patent/TN2014000491A1/en unknown
- 2014-11-25 DO DO2014000268A patent/DOP2014000268A/en unknown
- 2014-12-08 IL IL236131A patent/IL236131A0/en active IP Right Grant
- 2014-12-10 MA MA37666A patent/MA37666B1/en unknown
- 2014-12-11 CL CL2014003374A patent/CL2014003374A1/en unknown
- 2014-12-11 CR CR20140571A patent/CR20140571A/en unknown
- 2014-12-16 PH PH12014502803A patent/PH12014502803A1/en unknown
- 2014-12-18 EC ECIEPI201432215A patent/ECSP14032215A/en unknown
- 2014-12-18 NI NI201400146A patent/NI201400146A/en unknown
- 2014-12-18 CO CO14278352A patent/CO7151486A2/en unknown
-
2015
- 2015-01-20 ZA ZA2015/00408A patent/ZA201500408B/en unknown
- 2015-07-22 HK HK15106985.7A patent/HK1206349A1/en not_active IP Right Cessation
-
2016
- 2016-03-14 PH PH12016500498A patent/PH12016500498A1/en unknown
- 2016-04-29 CR CR20160202A patent/CR20160202A/en unknown
- 2016-06-28 AR ARP160101953A patent/AR105176A2/en unknown
-
2017
- 2017-03-06 HR HRP20170359TT patent/HRP20170359T1/en unknown
- 2017-03-08 ME MEP-2017-61A patent/ME02633B/en unknown
- 2017-03-13 CY CY20171100314T patent/CY1119505T1/en unknown
- 2017-11-03 AU AU2017254965A patent/AU2017254965B2/en not_active Ceased
-
2018
- 2018-02-09 JP JP2018021595A patent/JP6509393B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN10088A (en) | ||
| PH12016501192A1 (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
| MD20140109A2 (en) | Indole and indazole compounds that activate AMPK | |
| WO2012096929A3 (en) | Heteroaryl compounds and methods of use thereof | |
| MX351368B (en) | Heteroaryl compounds and methods of use thereof. | |
| MD20150091A2 (en) | Anti-viral compounds | |
| CL2012002487A1 (en) | Compounds derived from imidazo [1,2-a] pyrazine, pde10 inhibitors; pharmaceutical composition that includes them; process to prepare the pharmaceutical composition; Useful for the treatment of neurological, psychiatric or metabolic diseases such as schizophrenia, parkinson and diabetes, among others. | |
| PH12015500860A1 (en) | 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders | |
| MX2011008825A (en) | Substituted 3-aminoisoxazolopyridines as kcnq2/3 modulators. | |
| MX2011008662A (en) | Substituted 2-mercapto-3-aminopyridines as kcnq2/3 modulators. | |
| MX2011009338A (en) | Substituted 3-amino-2-mercaptoquinolines as kcnq2/3 modulators. | |
| ZA201407010B (en) | Process for the preparation of branched polybutadiene having high content of 1,4-cis units | |
| WO2016005962A3 (en) | Stable liquid formulations of cyclophosphamide and processes | |
| IN2014DN09584A (en) | ||
| MY192609A (en) | Substituted bicyclic heteroaryl compounds as rxr agonists | |
| NZ702239A (en) | Heteroaryl compounds and methods of use thereof | |
| NZ707946A (en) | Hydantoin derivative | |
| CO7160082A2 (en) | A method to improve liver function | |
| MX338438B (en) | Isoindolinone derivatives. | |
| WO2013114403A8 (en) | Substituted 4,5-dihydro-2h-benzo[e]indazole-9-carboxylates for the treatment of diabetes and related disorders |